Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
Study sponsor: Biomea Fusion Inc. · BMEA
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-06Estimated
Enrollment · participants60Estimated
Source updated2026-10-20Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.